Wednesday, October 13, 2010

Preliminary ACE-031 Results

Acceleron Presents Preliminary ACE-031 Results from a Phase 1 Multiple Ascending Dose Study in Healthy Volunteers

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers. ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by blocking proteins that inhibit muscle growth. In the trial, ACE-031 was generally well-tolerated with rapid and sustained effects on muscle, bone and fat. Preliminary results from this randomized, placebo-controlled study were presented at the 15th International Congress of the World Muscle Society in Kumamoto, Japan.

Read more:


Anonymous said...

thanks for the post

Anonymous said...

Hey, I can't view your site properly within Opera, I actually hope you look into fixing this.

Anonymous said...

hello!This was a really wonderful post!
I come from roma, I was fortunate to seek your blog in google
Also I obtain much in your blog really thanks very much i will come daily